INOVIO Pharmaceuticals products
DNA Medicines Technology
SynCon - Precisely Designed Plasmids
INOVIO’s DNA medicines are made using a process called SynCon®. SynCon uses a proprietary computer algorithm that has been designed to identify and optimize the DNA sequence of the target antigen, whether it is a virus or a tumor. Once this sequence has been determined, the DNA is synthesized or reorganized, and manufacturing can begin.
Cellectra - Proprietary Smart Devices
INOVIO’s DNA medicines deliver optimized plasmids directly into cells intramuscularly or intradermally using one of INOVIO’s proprietary hand-held CELLECTRA® smart devices. The CELLECTRA device uses a brief electrical pulse to reversibly open small pores in the cell to allow the plasmids to enter, overcoming a key limitation of other DNA and other nucleic acid approaches, such as mRNA. INOVIO has employed its CELLECTRA®2000 smart delivery device for over a decade in more than 40 oncology and infectious disease clinical trials, including those for COVID-19 disease. For intramuscular delivery, INOVIO uses its CELLECTRA 5PSP in its Phase 3 clinical trial for VGX-3100. INOVIO is developing its next-generation CELLECTRA 3PSP for intradermal delivery.
INOVIO - Model IN VIVO - DNA Medicines Technology
INOVIO’s DNA medicines deliver optimized plasmids directly into cells intramuscularly or intradermally using one of INOVIO’s proprietary hand-held CELLECTRA smart devices. Once inside the cell, the DNA plasmids enable the cell to produce the targeted antigen. The antigen is processed naturally in the cell and triggers the desired T cell and antibody-mediated immune response. Administration with the CELLECTRA device ensures that the DNA medicine is efficiently delivered directly into the body’s cells, where it can go to work to drive an immune response.